Marksans Pharma shares gain 4.5% after subsidiary’s New York facility gets EIR from USFDA

Your email address will not be published. Required fields are marked *

Name  *

Email  *

Website

Add Comment *

Save my name, email, and website in this browser for the next time I comment.

Post Comment